13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • GO29365

    Acronym: 

    GO29365

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase I Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase Ib/II study evaluating the safety, tolerability and anti-tumour activity of polatuzumab vedotin (DCDS4501A) in combination with Rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relapsed or refractory follicular or diffuse large B-cell lymphoma

    Lay Summary

    Sponsor / Cooperative group

    Roche

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting